Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4249836 | 0.91 | GRIN2B (0.40) | ACHECHRM2CHRM3SIGMAR1S1PR1 | |
| SCHEMBL4248188 | 0.89 | ACHE (0.42) | ACHEMEN1KMT2ACHRM2CHRM3 | |
| SCHEMBL4238209 | 0.88 | PKM (0.42) | ACHEMEN1KMT2ACHRM2CHRM3 | |
| SCHEMBL4237268 | 0.87 | MEN1 (0.42) | ACHEMEN1KMT2ASIGMAR1S1PR1 | |
| SCHEMBL4242086 | 0.87 | MEN1 (0.42) | ACHEMEN1KMT2ASIGMAR1S1PR1 | |
| SCHEMBL4237318 | 0.83 | SIGMAR1 (0.44) | MEN1KMT2ASIGMAR1S1PR1S1PR5 | |
| SCHEMBL4240892 | 0.83 | SIGMAR1 (0.42) | ACHESIGMAR1 | |
| SCHEMBL4244127 | 0.80 | KMT2A (0.45) | ACHEMEN1KMT2ACHRM2CHRM3 | |
| SCHEMBL4238450 | 0.80 | MEN1 (0.41) | ACHEMEN1KMT2ASIGMAR1KDM4E | |
| SCHEMBL4248181 | 0.79 | ACHE (0.38) | ACHEMEN1KMT2AS1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | claimed |
| US-20090012116-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM2, CHRM5 | ACHE 108/4885MEN1 1950/4885KMT2A 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.